Evidence map›Paper›PMID 33799006›Full record

ArticleCancer treatment and research communications2021

Expression of CD40L on CD4

Owen Ngalamika, Musonda Kawimbe, Marie Claire Mukasine

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer treatment and research communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. CD8Research square · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Owen NgalamikaDermatology and Venereology Division, Adult University Teaching Hospital, Lusaka, Zambia; University of Zambia School of Medicine, Lusaka, Zambia; HHV8 Research Molecular Virology Laboratory, University Teaching Hospital, Lusaka, Zambia. Electronic address: owen_ngalamika@yahoo.com.
Musonda KawimbeHHV8 Research Molecular Virology Laboratory, University Teaching Hospital, Lusaka, Zambia.
Marie Claire MukasineHHV8 Research Molecular Virology Laboratory, University Teaching Hospital, Lusaka, Zambia.
University Teaching Hospital · ZM

Funding

Zambia AIDS Malignancies Diagnosis and Pathogenesis Program SupplementU54CA221204 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2017 to 2022
$3.8M
KSHV,HIV and the Kaposi's Sarcoma Tumor NicheR01CA228178 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2018 to 2024
$2.9M
AIDS Malignancies Training and Research International Program (AMTRIP)D43TW010354 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI Chipepo Kankasa, Charles Wood · 2016 to 2026
$2.8M
Biomarkers of Kaposi sarcoma recrudescence in ZambiaK43TW011095 · FIC · UNIVERSITY OF ZAMBIA · PI NGALAMIKA, OWEN · 2018 to 2023
$721k
FIC NIH HHS D43 TW010354FIC NIH HHS K43 TW011095NCI NIH HHS R01 CA228178NCI NIH HHS U54 CA221204
6 · The paper itself

Abstract

Kaposi's sarcoma (KS) is a malignancy of vascular origin. It is caused by the Kaposi's sarcoma-associated herpes virus (KSHV). Immune dysregulation is a key feature in the development and progression of KS. The main aim of this study was to determine and compare circulating CD4

Indexed as

AdultAIDS-Related Opportunistic InfectionsCD40 LigandCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCross-Sectional StudiesFemaleHumansImmunophenotypingKiller Cells, NaturalMaleMemory T CellsNatural Killer T-CellsProgrammed Cell Death 1 ReceptorSarcoma, KaposiCD40 LigandPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD40LHIVKaposi's sarcomaNatural killer cellsPD1T cell subsets

Identifiers

PMID33799006
PMCPMC8127409
OpenAlexW3137949042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.